Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
about
Herbal medicines and nonalcoholic fatty liver diseaseThe Natural Course of Non-Alcoholic Fatty Liver DiseaseInsulin resistance in development and progression of nonalcoholic fatty liver diseaseType 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the SpotlightNonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of EvaluationLiver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.Nonalcoholic fatty liver disease: new treatmentsDefinitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic ReviewMolecular Pathogenesis of NASHPathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal CellsEpigenetics in liver disease: from biology to therapeuticsTransient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVSirtuins and nonalcoholic fatty liver diseaseSleep Disruption and Daytime Sleepiness Correlating with Disease Severity and Insulin Resistance in Non-Alcoholic Fatty Liver Disease: A Comparison with Healthy ControlsRecommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic SteatohepatitisPerspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future TherapiesPromising therapies for treatment of nonalcoholic steatohepatitis.Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver diseaseThe Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis.Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patientsAge as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment of non-alcoholic fatty liver disease.Non-alcoholic fatty liver disease: An expanded reviewPrevalence of Non Alcoholic Fatty Liver Disease and its Association with Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus.Characterization of transcriptional modules related to fibrosing-NAFLD progression.Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.Status of hepatic DNA methylome predetermines and modulates the severity of non-alcoholic fatty liver injury in miceNo effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.Influence of Ethnicity on the Accuracy of Non-Invasive Scores Predicting Non-Alcoholic Fatty Liver Disease.Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver DiseaseDual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in ManPoor Inter-test Reliability Between CK18 Kits as a Biomarker of NASHHistology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance.Phosphorylated IGFBP-1 as a non-invasive predictor of liver fat in NAFLD.Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.Non-alcoholic fatty liver disease and diabetes.
P2860
Q26738524-B16CF10D-FAAB-4AFF-9A0F-EF8C40C66463Q26746947-7C238D37-A115-4F92-9F64-4E0E66EEECB0Q26748687-D8C87B17-2DBE-4BA3-9BA4-B50D4FBD7E13Q26752583-3CA5C62F-33B6-4E20-BD95-2AF190C35AD8Q26771722-A9709D7D-33E9-4BA7-9840-257FDC46E074Q26780252-A07CA5CE-9502-4B37-B5A9-EF6687ECDF9DQ27021161-42DDBE7B-3F07-4689-8130-8DFF3BC5F76CQ28070408-064839F9-4C5E-475F-AA64-64109B432E7CQ28071265-808749F9-D9BC-49A4-9B86-2AAA5695C14DQ28071596-82ED4C11-B549-468A-A30F-35AB0CD15417Q28079271-FC9CB126-8E18-4C36-B7B6-402C1430F58FQ28079445-77FBE0FC-BA65-471B-98CA-26B5A3069818Q28079826-E955251E-88B8-46D0-8F70-42AD4847E53AQ28079953-7F54AFBF-7C28-44B0-840D-13856AFC525DQ28551009-1B4C9D24-AB40-4FB8-81C5-3B257068CC4AQ28607750-C677EC51-7905-40C1-9421-5626A17EFAA2Q30234444-A0594524-17B5-414A-950C-F53924C33BD3Q30248578-5511F718-68EF-4892-82FE-034DAB07F115Q30376231-4A5F6F50-8909-4131-A523-73910DDF696EQ30382395-61A64022-7F80-4441-BD1C-3169CD8E4FF7Q31134971-E6B62AA7-C6FA-4CA5-BB4E-F6FC24704920Q33574413-431FAC78-ACCA-462C-82C6-A2086A99220FQ33594722-761B9961-05C3-46A7-A5D4-B02C097E4A3BQ33639969-A6637A90-425D-47D6-A33C-1C68A435A0AEQ33709456-E4B063BB-D903-4158-ACE9-2134CF2C3A37Q33789868-65EF2CF9-79C4-4D8F-AFC7-E7E5BA5FE696Q33832177-C92AEA68-D80A-454C-B303-EBC4FCB9879DQ33881352-DEF70EC0-0075-4C0C-B951-B97161205BE5Q35965687-998E69BA-AF6E-4960-8D3F-501BA7FF0D94Q35996623-5703C2FD-39F9-46D9-890B-8CE97873966CQ36063593-41D33801-8B19-42AD-896E-60CB3002119CQ36118420-7038DF67-77FA-4AD6-911F-099441B2E4BFQ36138443-E4137DD7-A346-4572-BA5E-E1D449791DFEQ36431676-857F7AAE-DB1A-46AC-8C1E-2C3D06C7FF6FQ36600213-97742C70-6102-46BF-8035-2A896A134A96Q36791363-FFD69B84-4B92-472D-9CAA-F9F09392B603Q36796030-D4628144-E670-497E-AB1B-9063F6F28B84Q36810083-47EC12F3-95A4-4C4C-A719-046DEF5A349AQ36818351-0D2B52D7-9BB5-42E5-8DA4-66CA26185EBAQ37091659-897E6940-FB00-403A-BAA1-E0D1A838C37F
P2860
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Evidence of NAFLD progression ...... nosis and clinical management.
@en
type
label
Evidence of NAFLD progression ...... nosis and clinical management.
@en
prefLabel
Evidence of NAFLD progression ...... nosis and clinical management.
@en
P2093
P50
P1476
Evidence of NAFLD progression ...... nosis and clinical management.
@en
P2093
Christopher P Day
Elsbeth Henderson
P304
P356
10.1016/J.JHEP.2014.11.034
P577
2014-12-01T00:00:00Z